Edition:
India

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

35.78USD
23 Feb 2017
Change (% chg)

$0.53 (+1.50%)
Prev Close
$35.25
Open
$35.57
Day's High
$35.92
Day's Low
$35.40
Volume
595,042
Avg. Vol
695,768
52-wk High
$57.81
52-wk Low
$30.90

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 0.71
Market Cap(Mil.): $71,137.97
Shares Outstanding(Mil.): 2,012.56
Dividend: 0.66
Yield (%): 3.71

Financials

  NVO.N Industry Sector
P/E (TTM): 16.80 28.90 29.71
EPS (TTM): 2.13 -- --
ROI: 75.08 13.43 12.94
ROE: 82.23 14.33 14.09

BRIEF-Novo Nordisk proposes Novo A/S CEO and former BG chief as board members

* Says the board of directors proposes election of Kasim Kutay and Helge Lund as new members of the board of directors at the annual general meeting

12:52pm IST

European shares fall weighed down by poor earnings; Reckitt up

* Novo Nordisk, Deutsche Bank among top losers after poor results

02 Feb 2017

European shares edge lower on disappointing company updates

LONDON, Feb 2 European shares fell on Thursday after disappointing company updates, with Denmark's Novo Nordisk leading the market down and Finnish retailer Kesko weakening on lower-than-expected sales.

02 Feb 2017

BRIEF-Novo Nordisk CEO: We are not concerned about Trump

Feb 2 Drugmaker Novo Nordisk CEO Lars Fruergaard Jorgensen made the following comments during a call with journalists:

02 Feb 2017

Drugmaker Novo Nordisk lowers 2017 sales, profit outlook

COPENHAGEN, Feb 2 Denmark's Novo Nordisk , the world's top maker of diabetes drugs, said fourth-quarter operating profit came in a touch below forecasts and lowered its 2017 operating profit and sales growth outlook measured in local currency terms.

02 Feb 2017

BRIEF-Novo Nordisk cuts 2017 sales, profit outlook in local currencies

* Says 2017 sales growth is expected to be in the range of a decline of 1 percent to a growth of 4 percent measured in local currencies

02 Feb 2017

Stock futures signal slightly higher market open. For more see the European equities LiveMarkets blog

LONDON, Jan 31 Live coverage of European markets now available on cpurl://apps.cp./cms/?pageId=livemarkets

31 Jan 2017

Sanofi, Novo Nordisk and Lilly named in patients' price fixing suit

NEW YORK, Jan 30 Three of the biggest makers of diabetes treatments, Sanofi SA, Novo Nordisk and Eli Lilly & Co, were named in a class action lawsuit about price fixing filed by a group of patients.

31 Jan 2017

BRIEF-Novo Nordisk to invest $144 mln in University of Oxford research centre

* Says enters collaboration with University of Oxford on type 2 diabetes and invests 115 million pounds ($144.52 million)in new research centre

30 Jan 2017

Drugmaker Novo Nordisk bets $145 mln on post-Brexit UK science

LONDON, Jan 30 Novo Nordisk, the world's top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research centre in Britain, undeterred by Brexit.

30 Jan 2017

More From Around the Web

Competitors

  Price Chg
Sanofi SA (SASY.PA) €79.72 -0.41
Eli Lilly and Co (LLY.N) $82.92 +0.37

Earnings vs. Estimates